Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART

• Published in: Journal of clinical virology Vol. 37; no. 4; pp. 300 - 304
• Main Authors: Lehmann, Clara, Däumer, Martin, Boussaad, Ibrahim, Sing, Tobias, Beerenwinkel, Niko, Lengauer, Thomas, Schmeisser, Norbert, Wyen, Christoph, Fätkenheuer, Gerd, Kaiser, Rolf
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.12.2006; Elsevier Science
• Subjects: Adult; Aged; Antiretroviral Therapy, Highly Active; Biological and medical sciences; Chemokine receptors; Female; Fundamental and applied biological sciences. Psychology; HAART failure; HIV; HIV Infections - metabolism; HIV Infections - therapy; HIV-1 - metabolism; HIV-1 - pathogenicity; HIV-1 - physiology; Human immunodeficiency virus; Human viral diseases; Humans; Infectious diseases; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Receptors, CCR5 - metabolism; Receptors, Chemokine - metabolism; Receptors, CXCR4 - metabolism; Resistance; Treatment Failure; Tropism - physiology; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Virology; Virus tropism; Resistance; Virus tropism; HIV; HAART failure; Chemokine receptors; Tropism; Immunopathology; Microbiology; Retroviridae; AIDS; Chemokine receptor; Immune deficiency; Lentivirus; Virology; Infection; Virus; Treatment; Viral disease; Antiviral; Human immunodeficiency virus; Failure
• ISSN: 1386-6532; 1873-5967
• DOI: 10.1016/j.jcv.2006.08.008

Disease progression in HIV infection has been associated with switch of viral coreceptor usage from CCR5 to CXCR4. To investigate the relationship between HIV-coreceptor tropism and clinical and virological outcome in 40 heavily pretreated patients over time. Coreceptor phenotype was predicted after sequencing the V3 loop of the HIV glycoprotein 120. Coreceptor use was stable during observation time in 87% of patients, and CCR5 tropism was predominant. Viral mutations in the pol gene and clinical parameters were not predictive for coreceptor switching. Even in patients with repeated HAART failure, CCR5 antagonists might be a valuable treatment option.